Início › Leucemia Mieloide Aguda › Rhode Island
Ensaios clínicos de Leucemia Mieloide Aguda em Rhode Island
11 estudos para Leucemia Mieloide Aguda estão buscando participantes em locais em Rhode Island.
Cidades em Rhode Island
Texto oficial do estudo (Inglês)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Kent Hospital, Warwick
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Rhode Island Hospital, Providence
RecrutandoFase 2
Idades de 18 a 59 · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Rhode Island Hospital, Providence
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05564390Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Clinical Trial Site, Providence
RecrutandoFase 3
Idades 12 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07211958Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Rhode Island Hospital, Providence
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Rhode Island Hospital, Providence
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Rhode Island Hospital, Providence
RecrutandoFase 2
Idades de 18 a 59 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Rhode Island Hospital, Providence
RecrutandoFase 3
6 Months – 21 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT04293562The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Rhode Island Hospital, Providence
RecrutandoFase 1/2
Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- University of Rhode Island, Providence
RecrutandoFase 2/3
Idades de 18 a 80 · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT06788756Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
- Lifespan Health System Rhode Island Hospital, Providence
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 10 de jul. de 2026 · NCT05442216Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.